| Sildenafil |
EU/1/05/318/003 |
Revatio, Powder for oral suspension, 10 mg/ml 90 ml (32,27 g), mg, Pack: 1 |
Pfizer Limited, Обединено Кралство |
Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Poce-sur-Cisse, Франция |
444.05 |
88.81 |
532.86 |
4% |
10 |
454.05 |
90.81 |
544.86 |
16% |
25 |
479.05 |
95.81 |
574.86 |
|
НСР-7899/25.01.2016. |
09.02.2016 |
09.02.2016 |
Неактивен |
3311 |
| Sildenafil |
EU/1/05/318/003 |
Revatio, Powder for oral suspension, 10 mg/ml 90 ml (32,27 g), mg, Pack: 1 |
Pfizer Limited, Обединено Кралство |
Fareva Amboise, Zone Industrielle, 29 route des Industries, 37530 Poce-sur-Cisse, Франция |
449.33 |
89.87 |
539.2 |
4% |
10 |
459.33 |
91.87 |
551.2 |
16% |
25 |
484.33 |
96.87 |
581.2 |
промяна на обстоятелства Решение НСР-5257/10.12.2014 |
НСР-4901/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3311 |
| Sildenafil |
EU/1/05/318/003 |
Revatio, Powder for oral suspension, 10 mg/ml 90 ml (32,27 g), mg, Pack: 1 |
Pfizer Limited, Обединено Кралство |
Pfizer PGM, Zone Industries, 37530, Pocesur-Cisse, France |
460.75 |
92.15 |
552.9 |
4% |
10 |
470.75 |
94.15 |
564.9 |
16% |
25 |
495.75 |
99.15 |
594.9 |
|
НСР-2433/21.01.2014 |
05.02.2014 |
05.02.2014 |
Неактивен |
3311 |
| Eltrombopag |
EU/1/10/ 612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
Novartis Europharm Limited, Ирландия |
Glaxo Wellcome S.A., Испания; Novartis Pharmaceuticals UK Limited, Обединено кралство; Novartis Pharma GmbH, Германия |
3128.02 |
625.6 |
3753.62 |
4% |
10 |
3138.02 |
627.6 |
3765.62 |
16% |
25 |
3163.02 |
632.6 |
3795.62 |
Промяна на обстоятелствата НСР-16373/02.08.2018; НСР-17819/24.01.2019 |
НСР-8242/22.02.2016; НСР-10756/27.10.2016; НСР-17578/20.12.2018; НСР-18294/28.03.2019 |
04.01.2019 |
02.05.2019 |
Заличен |
3232 |
| Eltrombopag |
EU/1/10/ 612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
Novartis Europharm Limited, Ирландия |
Glaxo Wellcome S.A., Испания; Novartis Pharmaceuticals UK Limited, Обединено кралство; Novartis Pharma GmbH, Германия |
3128.02 |
625.6 |
3753.62 |
4% |
10 |
3138.02 |
627.6 |
3765.62 |
16% |
25 |
3163.02 |
632.6 |
3795.62 |
Промяна на обстоятелствата НСР-16373/02.08.2018; НСР-17819/24.01.2019 |
НСР-8242/22.02.2016; НСР-10756/27.10.2016; НСР-17578/20.12.2018 |
04.01.2019 |
02.03.2019 |
Неактивен |
3232 |
| Eltrombopag |
EU/1/10/ 612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
Novartis Europharm Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations), UK |
3128.02 |
625.6 |
3753.62 |
4% |
10 |
3138.02 |
627.6 |
3765.62 |
16% |
25 |
3163.02 |
632.6 |
3795.62 |
Промяна на обстоятелствата НСР-16373/02.08.2018 |
НСР-8242/22.02.2016; НСР-10756/27.10.2016; НСР-17578/20.12.2018 |
04.01.2019 |
02.02.2019 |
Неактивен |
3232 |
| Eltrombopag |
EU/1/10/612/002 |
REVOLADE, Film coated tablet, 25, mg, Pack: 28 |
Novartis Europharm Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
1564 |
312.8 |
1876.8 |
4% |
10 |
1574 |
314.8 |
1888.8 |
16% |
25 |
1599 |
319.8 |
1918.8 |
Промяна на обстоятелствата НСР-16372/02.08.2018 |
НСР-8676/06.04.2016.; НСР-10996/24.11.2016; НСР-17882/07.02.2019 |
22.02.2019 |
02.03.2019 |
Активен |
3568 |
| Eltrombopag |
EU/1/10/612/002 |
REVOLADE, Film coated tablet, 25, mg, Pack: 28 |
Novartis Europharm Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
1586.37 |
317.27 |
1903.64 |
4% |
10 |
1596.37 |
319.27 |
1915.64 |
16% |
25 |
1621.37 |
324.27 |
1945.64 |
Промяна на обстоятелствата НСР-16372/02.08.2018 |
НСР-8676/06.04.2016.; НСР-10996/24.11.2016 |
10.12.2016 |
02.09.2018 |
Неактивен |
3568 |
| Eltrombopag |
EU/1/10/ 612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
Novartis Europharm Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations), UK |
3173.49 |
634.7 |
3808.19 |
4% |
10 |
3183.49 |
636.7 |
3820.19 |
16% |
25 |
3208.49 |
641.7 |
3850.19 |
Промяна на обстоятелствата НСР-16373/02.08.2018 |
НСР-8242/22.02.2016; НСР-10756/27.10.2016 |
11.11.2016 |
02.09.2018 |
Неактивен |
3232 |
| Eltrombopag |
EU/1/10/612/002 |
REVOLADE, Film coated tablet, 25, mg, Pack: 28 |
Novartis Europharm Limited, Обединено Кралство |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
1586.37 |
317.27 |
1903.64 |
4% |
10 |
1596.37 |
319.27 |
1915.64 |
16% |
25 |
1621.37 |
324.27 |
1945.64 |
|
НСР-8676/06.04.2016.; НСР-10996/24.11.2016 |
10.12.2016 |
02.01.2017 |
Неактивен |
3568 |
| Eltrombopag |
EU/1/10/ 612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
Novartis Europharm Limited, Обединено Кралство |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations), UK |
3173.49 |
634.7 |
3808.19 |
4% |
10 |
3183.49 |
636.7 |
3820.19 |
16% |
25 |
3208.49 |
641.7 |
3850.19 |
|
НСР-8242/22.02.2016; НСР-10756/27.10.2016 |
11.11.2016 |
02.12.2016 |
Неактивен |
3232 |
| Eltrombopag |
EU/1/10/612/002 |
REVOLADE, Film coated tablet, 25, mg, Pack: 28 |
Novartis Europharm Limited, Обединено Кралство |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
1597.44 |
319.49 |
1916.93 |
4% |
10 |
1607.44 |
321.49 |
1928.93 |
16% |
25 |
1632.44 |
326.49 |
1958.93 |
|
НСР-8676/06.04.2016. |
22.04.2016 |
22.04.2016 |
Неактивен |
3568 |
| Eltrombopag |
EU/1/10/ 612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
Novartis Europharm Limited, Обединено Кралство |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations), UK |
3232.65 |
646.53 |
3879.18 |
4% |
10 |
3242.65 |
648.53 |
3891.18 |
16% |
25 |
3267.65 |
653.53 |
3921.18 |
|
НСР-8242/22.02.2016 |
09.03.2016 |
09.03.2016 |
Неактивен |
3232 |
| Eltrombopag |
EU/1/10/ 612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
Novartis Europharm Limited, Обединено Кралство |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations), UK |
3232.73 |
646.55 |
3879.28 |
4% |
10 |
3242.73 |
648.55 |
3891.28 |
16% |
25 |
3267.73 |
653.55 |
3921.28 |
промяна обстоятелства НСР-6992/24.08.2015 |
НСР-6410/12.06.2015. |
26.06.2015 |
26.06.2015 |
Неактивен |
3232 |
| Eltrombopag |
EU/1/10/612/002 |
REVOLADE, Film coated tablet, 25, mg, Pack: 28 |
Novartis Europharm Limited, Обединено Кралство |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
1601.71 |
320.34 |
1922.05 |
4% |
10 |
1611.71 |
322.34 |
1934.05 |
16% |
25 |
1636.71 |
327.34 |
1964.05 |
промяна обстоятелства НСР-6993/24.08.2015 |
НСР-5575/05.02.2015. |
19.02.2015 |
19.02.2015 |
Неактивен |
3568 |
| Eltrombopag |
EU/1/10/ 612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
GlaxoSmithKline Trading Services Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations), UK |
3376.96 |
675.39 |
4052.35 |
4% |
10 |
3386.96 |
677.39 |
4064.35 |
16% |
25 |
3411.96 |
682.39 |
4094.35 |
|
НСР-4739/02.10.2014 |
16.10.2014 |
16.10.2014 |
Неактивен |
3232 |
| Eltrombopag |
EU/1/10/612/002 |
REVOLADE, Film coated tablet, 25, mg, Pack: 28 |
GlaxoSmithKline Trading Services Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
1716.1 |
343.22 |
2059.32 |
4% |
10 |
1726.1 |
345.22 |
2071.32 |
16% |
25 |
1751.1 |
350.22 |
2101.32 |
|
НСР-3591/23.05.2014 |
06.06.2014 |
06.06.2014 |
Неактивен |
3568 |
| Eltrombopag |
EU/1/10/612/002 |
REVOLADE, Film coated tablet, 25, mg, Pack: 28 |
GlaxoSmithKline Trading Services Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
1723.26 |
344.65 |
2067.91 |
4% |
10 |
1733.26 |
346.65 |
2079.91 |
16% |
25 |
1758.26 |
351.65 |
2109.91 |
|
НСР-857/09.08.2013 |
02.09.2013 |
02.09.2013 |
Неактивен |
3568 |
| Eltrombopag |
EU/1/10/612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
GlaxoSmithKline Trading Services Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
3446.56 |
689.31 |
4135.87 |
4% |
10 |
3456.56 |
691.31 |
4147.87 |
16% |
25 |
3481.56 |
696.31 |
4177.87 |
|
HCР-306/28.06.2013. |
17.07.2013 |
17.07.2013 |
Неактивен |
3232 |
| Eltrombopag |
EU/1/10/612/005 |
REVOLADE, Film coated tablet, 50, mg, Pack: 28 |
GlaxoSmithKline Trading Services Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
3833.43 |
766.69 |
4600.12 |
4% |
10 |
3843.43 |
768.69 |
4612.12 |
16% |
25 |
3868.43 |
773.69 |
4642.12 |
|
КЦ-1683/25.06.2010 |
15.07.2010 |
15.07.2010 |
Неактивен |
3232 |
| Eltrombopag |
EU/1/10/612/002 |
REVOLADE, Film coated tablet, 25, mg, Pack: 28 |
GlaxoSmithKline Trading Services Limited, Ирландия |
GlaxoOperation UK Ltd.(trading as Glaxo Wellcome Operations) , UK |
1916.71 |
383.34 |
2300.05 |
4% |
10 |
1926.71 |
385.34 |
2312.05 |
16% |
25 |
1951.71 |
390.34 |
2342.05 |
|
КЦ-1683/25.06.2010 |
15.07.2010 |
15.07.2010 |
Неактивен |
3568 |
| Atazanavir |
EU/1/03/267/004 |
REYATAZ, Capsule, hard, 150, mg, Pack: 60 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol- Myers Squibb S.R.L., Italy |
650.06 |
130.01 |
780.07 |
4% |
10 |
660.06 |
132.01 |
792.07 |
16% |
25 |
685.06 |
137.01 |
822.07 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-95/06.04.2015; промяна обстоятелства НСР-9177/27.04.2016 |
НСР-4658/25.09.2014.; НСР-15690/17.05.2018 |
02.05.2015 |
02.06.2018 |
Заличен |
3755 |
| Atazanavir |
EU/1/03/267/004 |
REYATAZ, Capsule, hard, 150, mg, Pack: 60 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol- Myers Squibb S.R.L., Italy |
650.06 |
130.01 |
780.07 |
4% |
10 |
660.06 |
132.01 |
792.07 |
16% |
25 |
685.06 |
137.01 |
822.07 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-95/06.04.2015; промяна обстоятелства НСР-9177/27.04.2016 |
НСР-4658/25.09.2014. |
02.05.2015 |
02.05.2015 |
Неактивен |
3755 |
| Atazanavir |
EU/1/03/267/004 |
REYATAZ, Capsule, hard, 150, mg, Pack: 60 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb, Rue du Docteur André Gilles, Epernon F-28230, France; Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, 19250 Meymac, France |
650.06 |
130.01 |
780.07 |
4% |
10 |
660.06 |
132.01 |
792.07 |
16% |
25 |
685.06 |
137.01 |
822.07 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-95/06.04.2015 |
НСР-4658/25.09.2014. |
02.05.2015 |
02.05.2015 |
Неактивен |
3755 |
| Atazanavir |
EU/1/03/267/004 |
REYATAZ, Capsule, hard, 150, mg, Pack: 60 |
Bristol-Myers Squibb Pharma EEIG, Обединено Кралство |
Bristol-Myers Squibb, Rue du Docteur André Gilles, Epernon F-28230, France; Bristol-Myers Squibb, Champ “Lachaud”, La Goualle, 19250 Meymac, France |
657 |
131.4 |
788.4 |
4% |
10 |
667 |
133.4 |
800.4 |
16% |
25 |
692 |
138.4 |
830.4 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-14/17.02.2015 |
НСР-3056/21.03.2014 |
16.03.2015 |
16.03.2015 |
Неактивен |
3755 |